| 1430-1500 | Pre-Congress workshop Biomechanics & Movement Workshop with BJC Health Brought to you by  |
|||
| 1130 – 1245 | Morning symposium 1 “Beyond remission” based on patients’ subjective experiences for improved RA control | Morning symposium 2 | Morning symposium 3 New evidence on the JAK inhibitor and its clinical implications for rheumatoid arthritis | |
Brought to you by  | Brought to you by  | Brought to you by  | ||
| 1315 – 1445 | Lunch symposium 1 Prospects for JAK inhibitors in the treatment of rheumatoid arthritis Brought to you by  | Lunch symposium 2 Basic and Clinical of Rheumatology Brought to you by  |
||
| 1740 – 1840 | Evening symposium 1 | Evening symposium 2 Treat-to-target in SLE: addressing short- and long-term treatment goals | Evening symposium 3 ILD in Focus: Time to prioritize the lung in CTDs | Evening symposium 4 Perspectives around the accumulated evidence for IL-6 in autoimmune disease |
| Brought to you by | Brought to you by | Brought to you by | Brought to you by  |
|
| 1130 – 1245 | Morning symposium 5 Treatment of Rheumatoid Arthritis: Past and Future | Morning symposium 6 To continue, taper or discontinue biologics – Implications on RA treatment outcomes | Morning symposium 7 | Morning symposium 8 |
Brought to you by  | Brought to you by | |||
| 1315 – 1445 | Lunch symposium 3 New insights for clinical practice in Spondyloarthritis, SpA Brought to you by  | Lunch symposium 4 New therapeutic alternatives for rheumatic diseases: Individualizing the treatment approach Brought to you by  |
||
| 1740 – 1840 | Evening symposium 5 Addressing Unmet Needs in RA and PsA: The Right Drug for the Right Patient | Evening symposium 6 The role of interleukin-6 in rheumatoid arthritis | Evening symposium 7 Denosumab, anti-RANKL antibody, for the treatment of joint destruction in RA. − From DRIVE & DESIRABLE studies | Evening symposium 8 |
Brought to you by  | Brought to you by  | Brought to you by | ||